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doi:10.1016/j.jtcvs.2006.07.057bjective: Heart failure therapies ranging from revascularization to remodeling to
eplacement are variably effective. Theoretically, endogenous repair via myocardial
egeneration would be an ideal therapy. This study examined the ability to initiate
egeneration by adenoviral-mediated expression of the cell cycle regulator cyclin
2. Our prior studies have demonstrated robust cyclin A2 transgene expression and
arked antiphosphorylated histone H3 activity with this strategy, indicating the
nduction of cardiomyocyte mitosis.
ethods: Adult male, Lewis rats underwent left anterior descending coronary artery
igation followed by intramyocardial delivery of either cyclin A2 adenoviral vector
n  8) or empty adeno-null vector as a control (n  8) into the peri-infarct border
one. In vivo myocardial function was analyzed by echocardiography and invasive
eft ventricular pressure catheter at 6 weeks, when the animals are traditionally in
eart failure. Hearts were explanted for immunoblotting and left ventricular geo-
etric analysis. Cellular proliferation was assessed by proliferating cellular nuclear
ntigen expression.
esults: Cyclin A2 hearts exhibited improved left ventricular function as com-
ared with controls including enhanced cardiac output (32  3.3 vs 26  5.0
L/min, P  .05), stroke volume (0.16  0.04 vs 0.11  0.04 mL, P  .05),
jection fraction (72%  7.4% vs 46.%  8.5%, P  .05), fractional shortening
35%  5.4% vs 19%  4.3%, P  .002), maximum pressure (72  9.3 vs 61  2.9
m Hg, P .05), and end-systolic pressure (67 7.0 vs 55 7.0 mm Hg, P .05).
nhanced myocardial preservation was demonstrated by enhanced left ventricular
order zone wall thickness. Increased myocardial proliferation was evidenced by
ncreased expression of proliferating cell nuclear antigen expression in cyclin
2-treated hearts.
onclusions: In failing hearts, targeted delivery of cyclin A2 improves hemody-
amic function, as measured by echocardiography and pressure catheter analysis,
reserves ventricular wall thickness, and may serve as an ideal myocardial regen-
rative therapy.
eart failure comprises a progressively prevalent global medical concern.
Present medical and surgical therapies have variable efficacy, prompting
investigation into molecular and cellular therapies to enhance myocardial
epair. To date, cellular transplantation appears to show the greatest promise.
owever, this approach is hindered by multiple limitations relating to cell harvest,
solation, propagation, delivery, and survival as well as controversy stemming from
he lack of clarity in defining the specific cell phenotype of greatest therapeutic
enefit. This is most apparent in the fact that there are several studies that demon-
trate functional improvement with the administration of unfractionated bone mar-
ow, indicating a lack of specificity and ill-defined mechanism to this therapy. As an
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CSPlternate approach, enhancing endogenous, preexistent
yocardial reparative mechanisms has been investigated.
ne specific strategy to endogenously enhance functional
yocardial tissue involves the induction of native cardio-
yocyte cell cycle reentry and replication.1-4 Cyclins and
yclin-dependent kinases (cdks) are cell cycle regulators
hat present potential therapeutic targets.5 Overexpression
f the restriction point control molecule cyclin D has
ielded positive initial findings.6
Cyclin A2 is a unique cell cycle regulator that controls
oth the G1/S transition into DNA synthesis as well as the
2/M entry into mitosis as compared with cyclin D, which
nly regulates a single point in the cell cycle. This enhanced
nvolvement in the cellular regenerative process makes cy-
lin A2 a particularly attractive therapeutic target.7 We have
reviously observed that transgenic mice constitutively ex-
ressing myocardial cyclin A2 develop postnatal cardiomy-
cyte mitosis and hyperplasia.8 There appears to be a 70%
ncrease in the calculated number of cardiomyocytes. Sub-
equently, we have demonstrated that cardiac delivery of an
denoviral vector encoding cytomegalovirus promoter-
riven cyclin A2 to rats with ischemic heart failure yields
yclin A2 transgene expression, initiates cardiomyocyte
roliferation as measured by Ki-67 expression and bro-
odeoxyuridine uptake, stimulates cardiomyocyte mitosis
s demonstrated by phosphohistone H3 expression, and
ncreases myofilament density.9 In this study, the impact of
his regenerative strategy on restoring ventricular function
nd geometry was investigated.
aterials and Methods
nimal Care
he protocol outlining this study was approved by the University
f Pennsylvania Institutional Animal Care and Use Committee. All
nimals received humane care in compliance with the “Guide for
he Care and Use of Laboratory Animals” published by the US
ational Institutes of Health (NIH Publication No. 85-23).
denoviral Vector Construction
ecombinant replication-deficient (E1, E3 deleted) adenoviruses
ontaining cyclin A2 driven by the cytomegalovirus promoter
ere produced and purified by the University of Iowa Gene
ransfer Vector core. Empty, replication-deficient adenovirus con-
Abbreviations and Acronyms
cdk  cyclin-dependent kinase
LAD  left anterior descending coronary artery
LVIDs  left ventricular end-systolic diameter
LVIDd left ventricular end-diastolic diameter
OCT  optimal cutting temperature
PCNA  proliferating cell nuclear antigenaining no transgene was used as a control (Adeno Null, University (
28 The Journal of Thoracic and Cardiovascular Surgery ● Aprif Iowa Gene Transfer Vector core). Direct intramyocardial injec-
ions of either adeno-cyclin A2 or adeno-null control virus were
erformed, and adenoviral transgene expression was confirmed by
nalysis of cyclin A2 protein levels by immunoblot and immuno-
istochemistry as previously described.9
nimal Surgery
dult male Lewis inbred rats (250-300 g) were purchased from
harles River Laboratories (Boston, Mass). The rats were anes-
hetized with intraperitoneal ketamine (75 mg/kg) and xylazine
7.5 mg/kg), intubated with a 14-gauge angiocatheter, and mechan-
cally ventilated with 1% isoflurane. A left fourth interspace tho-
acotomy was performed, and the proximal left anterior descend-
ng coronary artery (LAD) was ligated with a 7-0 polypropylene
uture. Infarction was confirmed by visible blanching of the region
t the time of ligation. As previously demonstrated, over a 6-week
eriod untreated animals will predictably progress into congestive
eart failure utilizing this model.10,11 This rodent experimental
odel will manifest active adverse ventricular remodeling during
he early postinfarction period, which will then lead to left ven-
ricular dilatation and contractile impairment. Immediately follow-
ng LAD ligation, the animals were randomized to either treatment
ith adeno-cyclin A2 (n  8) or adeno-null (n  8) virus. The
nimals then received direct intramyocardial injections of 5  109
article-forming units of virus into 5 separate locations in the
eri-infarct border zone area. A total volume of 250 L was
elivered, and injections were performed in a blinded fashion by a
ingle investigator. Because adenoviral vector transgene expres-
ion will typically peak around 1 week after delivery and taper off
y 3 to 4 weeks, the proliferative stimulus should be present during
he period of most active adverse ventricular remodeling.
chocardiographic Evaluation of Left
entricular Function
eft ventricular function was evaluated 6 weeks after initial left
nterior descending coronary artery ligation by transthoracic echo-
ardiography utilizing a Phillips Sonos 5500 revD system (Phillips
edical Systems N.A., Bothwell, Wash) with a 12-MHz trans-
ucer at an image depth of 3 cm. Rats were anesthetized with
ntraperitoneal ketamine (75 mg/kg) and xylazine (7.5 mg/kg) and
ntubated with a 14-gauge angiocatheter and maintained on 1%
soflurane for the duration of echocardiographic assessment. Echo-
ardiographic electrodes were placed on both the front limbs and
ight hind limb to obtain electrocardiographic tracings. Left
arasternal and left apical echocardiographic measurements
ere obtained in the dorsal recumbency position. Two-dimen-
ional left ventricular parasternal short-axis measurements were
sed to define internal diameters during systolic and diastolic
ime points. The left ventricular end-systolic diameter (LVIDs)
nd left ventricular end-diastolic diameter (LVIDd) were mea-
ured according to the American Society for Echocardiography
eading-edge method from at least 3 consecutive cardiac cycles.
LVIDd and LVIDs were then used to later derive diastolic
olume (1.047  LVIDd3), systolic volume (1.047  LVIDs3),
ractional shortening ([(LVIDdLVIDs/LVIDd)]  100), stroke
olume (diastolic volumesystolic volume), ejection fraction
stroke volume/diastolic volume  100), and cardiac output
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Pstroke volume heart rate). M-mode echocardiography was used
o define left ventricular diameters.
icrotip Conductance Catheter Assessment of Left
entricular Function
mmediately following echocardiography, all rats underwent me-
ian sternotomy for assessment of left ventricular pressures. A 2F
ressure conductance microcatheter (Millar Instruments, Houston,
ex) was inserted into the left ventricle through the apex of the
eart. Hemodynamic measurements were analyzed in a blinded
ashion utilizing Chart v4.1.2 software (AD Instruments, Colorado
prings, Col) and ARIA1 Pressure Volume Analysis software
Millar Instruments).
uantitative Evaluation of Ventricular Geometry
rior to explantation, hearts were perfused and rinsed with 10
L phosphate-buffered saline solution via the aortic root until
isual confirmation of blanching of the myocardium. The hearts
ere then explanted, and the left ventricular cavity was filled
ith optimal cutting temperature (OCT) embedding compound
xative through the aortic root at a fixed distending pressure.
he distended heart was placed in OCT, snap-frozen in liquid
itrogen, and stored in a 80°C freezer. Measurements of
entricular geometry were performed on 10 m-thick slices at
he level of the midpapillary muscle.
igure 1. Immunoblot of PCNA showing cellular proliferation in
yclin-treated animals versus controls. PCNA, proliferating cell
uclear antigen.
Figure 2. Immunofluorescent colocalization of PCNA a
cyclin-treated hearts (B), demonstrating cardiomyocyte pro
The Journal of ThoracicHematoxylin and eosin stain was performed to assess the
otential therapeutic effects of cyclin A2 on preserving ventricular
eometry. The ventricular border zone wall thickness was mea-
ured in 2 distinct sections and averaged. Measurements were
erformed on digitized photomicrographs using Scion Image pro-
essing software (Scion Corp, Frederick, Md) with standards of
nown millimeter length. For all analyses, the border zone was
efined as the viable myocardial tissue immediately adjacent to the
nfarct scar. All morphometric studies were performed by 2 ex-
miners who were blinded to treatment. Additionally, to gauge the
everity of myocardial fibrosis, Masson trichrome staining (Ac-
ustain Trichrome Stain, Sigma, St Louis, Mo) was also performed
n frozen sections from each tissue block. Collagen in the tissue
ections was stained blue using this trichrome method and quali-
atively compared.
uclear Proliferation as Assessed by Immunoblot and
mmunofluorescence
o determine DNA synthesis and proliferation, immunoblotting
or proliferating cell nuclear antigen (PCNA) was performed.
yocardial tissue obtained from the peri-infarct border zone was
omogenized in buffer consisting of 50 mM tris/HCl (pH 7.5), 100
M NaCl, 5 mM ethylenediamine-tetraacetic acid, 1% v/v Triton
-100, 1 mM NaF, 1 mM Na2VO4, 0.2 mM phenymethylsulfonyl
uoride, 10 g/mL leupeptin, and 10 g/mL aprotinin. Lysates
ere cleared by centrifugation at 12,000g for 10 minutes at 4°C
nd analyzed for protein content via the Bradford method (Bio-
ad, Hercules, Calif). Forty micrograms of each protein sample
ere then denatured at 70°C for 10 minutes and electrophoresed
nto a 4% to 12% gradient sodium dodecyl sulfate-polyacryl-
mide gel. Equal loading of protein was verified by Coomassie
lue staining. Proteins were transferred to Immobilon-P polyvi-
ylidane fluoride membranes (Millipore, Bedford, Mass), and im-
unoblotting was performed using a rabbit anti-rat PCNA poly-
lonal antibody (Santa Cruz Biotechnology, Santa Cruz, Calif).
roteins were visualized via horseradish peroxidase-conjugated
nti-rabbit antibody (Amersham Biosciences, Piscataway, NJ) and
hemiluminescence detection (Amersham Biosciences). Immuno-
-sarcomeric actin expression in null hearts (A) and innd 
liferation. PCNA, proliferating cell nuclear antigen.
and Cardiovascular Surgery ● Volume 133, Number 4 929
h
t
i
s
P
a
a
d
L
S
Q
m
S
R
E
P
I
P
c
c
w
E
T
f
H
E
F
L
L
S
C
L
M
E
b
Cardiopulmonary Support and Physiology Woo et al
9
CSPistochemical imaging of PCNA was performed on myocardial
hin sections (10 m) fixed in 4% paraformaldehyde, permeabil-
zed with Triton X-100, and blocked with 5% normal goat
erum. Proliferating cardiomyocytes were colocalized with
Figure 3. Echocardiographic functional evaluation of h
short-axis views of a control heart and a cyclin-treat
systole. C, Cyclin-treated heart in diastole. D, Cyclin-t
ABLE 1. Hemodynamic assessment of left ventricular
unction
Null
(n  8)
Cyclin
(n  8)
P
value
eart rate (bpm) 242 24 215 35 NS
jection fraction (%) 46 8.5 72 7.4 .002
ractional shortening (%) 19 4.3 35 5.4 .002
V internal diameter systole (mm) 5 0.5 3.9  0.7 .05
V end systolic volume (mm3) 130 40 70 40 .05
troke volume (mL) 0.11 0.04 0.16 .04 .05
ardiac output (mL/min) 26 5.0 32 3.3 .05
V wall thickness (mm) 1.9 0.3 2.6 0.4 .05
aximum pressure (mm Hg) 61 2.9 72 9.3 .05
nd-systolic pressure (mm Hg) 55 7.0 67 7.0 .05
pm, Beats per minute; LV, left ventricular.enhanced ejection fraction as compared with control hear
30 The Journal of Thoracic and Cardiovascular Surgery ● ApriCNA (1:600 rabbit anti-human PCNA, Abcam Cambridge, Mass)
nd -sarcomeric actin (1:700 mouse anti-rabbit -sarcomeric
ctin, Sigma Aldrich USA [St. Louis, MO]) as well as 4=,6-
iamidino-2-phenylindole and imaged (40 air magnification,
eica Microsystems, Wetzlar, Germany).
tatistical Analysis
uantitative data are expressed as means  standard error of the
ean. Statistical significance was evaluated using the unpaired
tudent t test for comparison between 2 means.
esults
xpression of Cyclin A2 Enhances Myocardial
roliferation
mmunoblotting via Western blot revealed higher levels of
CNA in the border zone of cyclin-treated hearts versus null
ontrols. There was no visible expression of PCNA in the
ontrol group, whereas a significant expression of PCNA
as evidenced in the cyclin-A2-treated group (Figure 1).
nhanced expression of PCNA signified enhanced nuclear
6 weeks postligation. Representative 2-D parasternal
eart. A, Control heart in diastole. B, Control heart in
d heart in systole. Cyclin-treated hearts demonstrateearts
ed h
reatets.
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Proliferation in the treatment group as compared with control.
ualitative immunofluorescent colocalization of PCNA and
-sarcomeric actin was observed in cyclin-treated animals
Figure 2).
yclin A2 Therapy Enhances Myocardial Function
chocardiographic analysis performed 6 weeks after ligation
howed statistically significant improvements in hemodynamic
unction as evidenced by left ventricular systolic volume, frac-
ional shortening, ejection fraction, stroke volume, and cardiac
utput (Table 1). Parasternal short-axis echocardiographic im-
ges demonstrate a significantly higher ejection fraction in
yclin-treated hearts versus controls (Figure 3). Left ventricular
all thicknesses were obtained from the parasternal long-axis
-mode view at the level of the papillary muscle and were
ignificantly thicker in the cyclin-treated group (Table 1). Rep-
esentative parasternal long-axis M-mode echocardiographic
mages from cyclin-treated and control hearts revealed sig-
ificantly preserved left ventricular end-systolic internal
iameter in cyclin-treated hearts versus controls (Figure 4).
n vivo pressure analysis by Millar catheter following echo-
ardiographic analysis yielded statistically significantly
igher maximum pressure and end-systolic pressure in
yclin-treated animals versus null controls (Table 1).
yclin A2 Therapy Enhances Myocardial Preservation
orphometric analysis for border zone ventricular thick-
ess showed significantly preserved left ventricular wall
hickness in cyclin-treated hearts as compared with controls
1.7  0.06 vs 1.5  0.06 mm, P  .05; Figure 5). Collagen
taining by Masson’s trichrome method revealed increased
iable myocardial tissue and a diminished scar fraction in
he cyclin-treated group when compared with null control
Figure 4. Representative parasternal long-axis M-mod
showing increased wall thickening in the cyclin-treatFigure 5). This was further seen as a reduction in collagen v
The Journal of Thoraciceposition in the border zone of cyclin-treated tissue
pecimens.
iscussion
ell cycle control entails a complex network of cyclins,
dks, cdk inhibitors, and multiple additional regulators.
ecause of their central role in this control, the cyclins serve
s attractive potential therapeutic targets to stimulate endog-
nous cardiomyocyte replication as a myocardial regenera-
ion and repair strategy. Cyclin A2 possesses several unique
eatures that render it a particularly appealing therapeutic
arget. It controls both major cell cycle transition points
1/S and G2/M. It is the only cyclin that is completely
ilenced after birth in mice, rats, and humans.8,12 The rate of
yclin A2 decrement matches the rate of cardiomyocyte cell
ycle withdrawl.11 Alternative targets proposed include the
and E family cyclins. However, the majority of mouse
issues develop without all 3 D-type cyclins.13 Cyclin E1
nd E2 knockout mice develop normally.14 On the other
and, a cyclin A2 knockout is embryonically lethal at em-
ryonic day 5.5.15
Thus we have focused upon the alteration of cyclin A2 as
potential heart failure treatment strategy. In a transgenic
yclin A2 mouse, we have previously reported cardiomyo-
yte mitosis and hyperplasia with up to a 70% increase in
he number of cardiomyocytes.8 With a postinfarction, ther-
peutic adenoviral delivery model, we have observed robust
yclin A2 transgene expression, cardiomyocyte prolifera-
ion and mitosis, and enhanced cardiac myofibril density.9
his particular model has been designed to yield high-level
ransient cyclin A2 expression during a 2- to 4-week period
fter myocardial infarction, during which significant ad-
w of a control heart (A) and cyclin-treated heart (B)
art.e vie
ed heerse remodeling stimuli are in effect. This limited time
and Cardiovascular Surgery ● Volume 133, Number 4 931
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CSPrame of transgene expression obviates any potential detri-
ental effects of uncontrolled, induced myocardial hyper-
lasia. This should also prevent any theoretical risk of
eoplasia. In fact, in the transgenic cyclin A2-treated ani-
als examined at age 1.5 years, despite constitutive myo-
ardial cyclin A2 expression, there was no histologic evi-
ence of neoplasia.8 The use of an adenoviral gene therapy
ystem can be criticized for its inherent limited ultimate
uman clinical translatability. However, as a research
odel, it is highly effective in providing high-level, targeted
xpression of a gene of interest. An additional limitation of
his approach, although theoretical, is the potential need for
nuclear localization signal on an adenoviral transgene de-
igned to affect a nuclear process. Although this has been
ostulated,16 there are multiple other studies that have demon -
trated that adenoviral transgene products can be properly
osttranslationally modified and targeted to the nucleus. 5,17-19
igure 5. Representative tissue sections stained by the Masson’s
richrome method show qualitatively less fibrosis (areas stained
lue) in cyclin-treated hearts versus control hearts. Planimetry
easurements of the ventricular wall thickness at border zone
arrows) show more-preserved wall thickness in cyclin-treated
nimals versus controls.nother possible limitation is that mechanistically, cyclin ex-
32 The Journal of Thoracic and Cardiovascular Surgery ● Apriression did not induce cardiomyocyte proliferation but rather
ardiomyocyte preservation through antiapoptotic or other cell
urvival pathways. In light of the extensive cardiomyocyte
roliferative and mitotic evidence observed in this and prior
xperiments, this seems less likely.
We have previously reported an extensive molecular and
ellular analysis of cardiomyocyte proliferation, mitosis,
nd regeneration.9 Thus for the current study, we selected
nly 1 proliferation marker to serve as an internal measure
f consistency between studies. The results with PCNA
eveal active myocardial proliferation within the cyclin A2-
reated animals. To examine the functional and geometric
enefits of myocardial regeneration, we elected to conduct
losed chest hemodynamic studies with transthoracic echo-
ardiography and then add corroborative data with intraven-
ricular pressure monitoring. The echocardiography data
eveal a uniform improvement in multiple myocardial func-
ional parameters in the cyclin group compared with con-
rols. Echocardiography provides an advantage over other
unctional assays in that it provides images and data that are
onceptually clinically pertinent. The histologic assays
omplement the echocardiographic data. The improvement
n ventricular geometry is displayed with both the scar
nalysis and the wall thickness assessment. These findings
re consistent with the induction of a myocardial reparative
echanism.
onclusions
herapeutic expression of cyclin A2 in infarcted hearts in-
uced proliferation and yielded echocardiographic and intra-
avitary pressure evidence of enhanced cardiac function as
ell as improved ventricular geometry. This cell cycle regu-
ator presents an attractive therapeutic target for the induction
f myocardial regeneration as a treatment for heart failure.
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iscussion
r Frank W. Sellke (Boston, MA). Joe, This is a very nicextension of what was presented at the American Heart Associa- c
The Journal of Thoracicion last year. It suggests that cyclin A2 may increase myocardial
egeneration and may have some therapeutic effect in treatment of
atients with chronic heart failure. I do have a couple of questions.
ow did the cyclin A2 affect other cell cycle proteins and factors
egulating myocardial regeneration and function? You may have
ooked at this previously, but do you have data?
Dr Y. Joseph Woo (Philadelphia, Pa). There is work done in
he transgenic mouse that constitutively expressed cyclin A2.
here did not appear to be much change in the other cell cycle
egulators. It seems that cyclin A was working independently of
anipulation of the other factors in the cell cycle regulation
athway.
Dr Sellke. The other question I have is a follow-up to that
uestion. How does manipulation of cyclin A2 affect long-term
iability? Could it just be a short-term effect with aggression of
hese new cells at a later date?
Dr Woo. Yes. Cyclin D has been evaluated in a similar fashion
y others. And although there is some controversy regarding
hether that is actually effective, similar results have been shown.
yclin D is notable for its control of the restriction point, that is,
he G1, theoretical G0 point interaction. Cyclin A is particularly
nteresting, primarily for the points that I mentioned earlier. It is a
-point controller. It drives G1 into DNA synthesis. There are
arious factors that can drive proliferation but not actually repli-
ation. You need to actually be able to push a cell into mitosis to
ake a difference. Cyclin A also regulates this control point.
urthermore, a cyclin A2 knockout is an embryonic lethal variant
nd also, it is totally silenced in the adult, thus making it an
ppealing therapeutic target.
Dr Sellke. Have you looked at targeting 2-cell cycle regulator
actors simultaneously?
Dr Woo. That is a good idea. I think the thing to do here would
e to use cyclins D and A. Cyclin D would allow the cells to come
ut of the theoretical G0 state, and then cyclin A would push the
ells into S and then over into M state.
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